Last updated: 2026-09-09 10:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Precision BioSciences, Inc. (DTIL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7.41, with a market capitalization of $206.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.53 to $9.62. This page covers its latest market performance, valuation, price trends and company information.
$206.18M | |
$7.41 | |
$710.11 | |
$3.53 | |
$7.47 | |
121.76K | |
403.21K | |
-- | |
$9.62 | |
$3.53 | |
-- | |
-- |
Precision BioSciences, Inc. (DTIL) is trading at $8.10 in pre-market trading as of 2026-09-08 23:31:00, up 8.43% ($0.63) from the previous close of $7.47
Pre-market trading shows how investors are pricing DTIL before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Precision BioSciences, Inc. (DTIL) moved from $7.78 to $7.41, representing a decline of 4.82% ($0.38).
The stock traded between $7.20 and $8.43 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 202.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.6%
DTIL is currently trading at $7.41, placing it 63.6% of the way from its 52-week low of $3.53 to its 52-week high of $9.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Precision BioSciences, Inc. (DTIL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.